Form 8-K - Current report:
SEC Accession No. 0001193125-19-106621
Filing Date
2019-04-15
Accepted
2019-04-15 16:41:33
Documents
8
Period of Report
2019-04-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d734812d8k.htm 8-K 23908
2 EX-1.1 d734812dex11.htm EX-1.1 240746
3 EX-4.1 d734812dex41.htm EX-4.1 71262
4 EX-4.2 d734812dex42.htm EX-4.2 100474
5 EX-5.1 d734812dex51.htm EX-5.1 12948
6 EX-99.1 d734812dex991.htm EX-99.1 9111
7 GRAPHIC g734812g0413042427073.jpg GRAPHIC 2771
8 GRAPHIC g734812g0413042427183.jpg GRAPHIC 1546
  Complete submission text file 0001193125-19-106621.txt   466007
Mailing Address 955 MASSACHUSETTS AVENUE 4TH FLOOR CAMBRIDGE MA 02139
Business Address 955 MASSACHUSETTS AVENUE 4TH FLOOR CAMBRIDGE MA 02139 857-529-8300
X4 Pharmaceuticals, Inc (Filer) CIK: 0001501697 (see all company filings)

EIN.: 273181608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38295 | Film No.: 19749010
SIC: 2836 Biological Products, (No Diagnostic Substances)